Glenmark Launches their First Nasal Spray For Treating Covid-19
The Mumbai-based pharmaceuticals company Glenmark on Wednesday launched a nasal spray in India to treat patients who are suffering from coronavirus. Nasal Spray named FabiSpray of Nitric Oxide, has been launched in collaboration with SaNOtize Research & Development Corp, a Canadian pharmaceutical company.
The company received manufacturing and marketing approval from India’s drug regulator, Drugs Controller General of India for Nitric Oxide Nasal Spray as part of approval process. The official statement reads, “Phase 3 trial in India met the key endpoints and demonstrated reduction of viral load of 94 per cent in 24 hours and 99 percent in 48 hours. Nitric Oxide Nasal Spray (NONS) was safe and well-tolerated in Covid-19 patients. Glenmark to market NONS under the brand name FabiSpray,”
The spray is designed to kill the Covid-19 ailment in the upper airways. According to the Nitric Oxide Nasal is sprayed over nasal mucosa which then acts as a physical and chemical barrier against the virus. It will prevent the virus from spreading to the lungs.
“This reaffirms our commitment of providing yet another safe and effective antiviral treatment for Covid-19, and we are confident that it will offer patients a much needed and timely therapy option,” Robert Crockart, chief commercial officer of Glenmark Pharmaceuticals Ltd, said in the statement.
The spray will also be distributed to other Asian markets such as Singapore, Malaysia, Hong Kong, Taiwan, Nepal, Brunei, Cambodia, Laos, Myanmar, Sri Lanka, Timor-Leste and Vietnam.
The country on Wednesday logged 71,365 fresh cases in the last 24 hours, pushing the overall data to reach 4,24,10,976. The death toll surged to 505,279, Meanwhile, the number of active cases has dropped below the 9,00,000 mark as the caseload fell at 8,92,828.
Continue Reading on The India Saga